| concept_id,system_id,dimension,code,label,extraction_id,note | |
| who_fgt.histotype.endometrioid,who_fgt/2020,histotype,endometrioid,Endometrioid carcinoma,ex_cap_histotype_endometrioid, | |
| who_fgt.histotype.serous,who_fgt/2020,histotype,serous,Serous carcinoma,ex_cap_histotype_serous, | |
| who_fgt.histotype.clear_cell,who_fgt/2020,histotype,clear_cell,Clear cell carcinoma,ex_cap_histotype_clear_cell, | |
| who_fgt.histotype.carcinosarcoma,who_fgt/2020,histotype,carcinosarcoma,Carcinosarcoma,ex_cap_histotype_carcinosarcoma,Almost exclusively p53abn once mimics are excluded (huvila/2024). | |
| who_fgt.histotype.dedifferentiated,who_fgt/2020,histotype,dedifferentiated,Dedifferentiated carcinoma,ex_cap_histotype_dedifferentiated,"CAP lists dedifferentiated and undifferentiated as two choices; endopath's Histotype fuses them into one. Reconcile in #36, not here." | |
| who_fgt.histotype.undifferentiated,who_fgt/2020,histotype,undifferentiated,Undifferentiated carcinoma,ex_cap_histotype_undifferentiated, | |
| who_fgt.histotype.mixed,who_fgt/2020,histotype,mixed,Mixed carcinoma,ex_cap_histotype_mixed, | |
| who_fgt.histotype.other_not_listed,who_fgt/2020,histotype,other_not_listed,Other histologic type not listed,ex_cap_histotype_other,The residual that makes the sibling set exhaustive. | |
| cap_uterus.histologic_grade.1,cap_uterus/5.1.0.0,histologic_grade,1,FIGO grade 1,ex_cap_grade_1,5% or less non-squamous solid growth. | |
| cap_uterus.histologic_grade.2,cap_uterus/5.1.0.0,histologic_grade,2,FIGO grade 2,ex_cap_grade_2,6% to 50% non-squamous solid growth. | |
| cap_uterus.histologic_grade.3,cap_uterus/5.1.0.0,histologic_grade,3,FIGO grade 3,ex_cap_grade_3,Greater than 50% non-squamous solid growth. | |
| cap_uterus.histologic_grade.high_grade_non_endometrioid,cap_uterus/5.1.0.0,histologic_grade,high_grade_non_endometrioid,High-grade (non-endometrioid carcinoma),ex_cap_grade_high_grade_non_endometrioid,Grade is gated on histotype: this choice exists only off the non-endometrioid branch. | |
| cap_uterus.lvsi.not_identified,cap_uterus/5.1.0.0,lvsi,not_identified,Not identified,ex_cap_lvsi_not_identified, | |
| cap_uterus.lvsi.present,cap_uterus/5.1.0.0,lvsi,present,Present,ex_cap_lvsi_present,Parent of the two focus-count choices. | |
| cap_uterus.lvsi.le_4_foci,cap_uterus/5.1.0.0,lvsi,le_4_foci,Less than or equal to 4 foci,ex_cap_lvsi_le4, | |
| cap_uterus.lvsi.ge_5_foci,cap_uterus/5.1.0.0,lvsi,ge_5_foci,Greater than or equal to 5 foci,ex_cap_lvsi_ge5,Same 5-focus cut FIGO 2023 uses for substantial. | |
| cap_uterus.lvsi.cannot_be_determined,cap_uterus/5.1.0.0,lvsi,cannot_be_determined,Cannot be determined,ex_cap_lvsi_cannot_be_determined,"indeterminate is a value, not a blank." | |
| figo_endo_2023.lvsi.negative,figo_endo/2023,lvsi,negative,LVSI negative (0 vessels),ex_figo2023_lvsi_thresholds, | |
| figo_endo_2023.lvsi.focal,figo_endo/2023,lvsi,focal,LVSI focal (<5 vessels),ex_figo2023_lvsi_thresholds, | |
| figo_endo_2023.lvsi.substantial,figo_endo/2023,lvsi,substantial,LVSI substantial/extensive (>=5 vessels),ex_figo2023_lvsi_substantial_rule,The paper dates the WHO rule as 2020 on page 6 and 2021 on page 4. | |
| promise.molecular_classification.polemut,promise/2017,molecular_classification,polemut,POLE-mutated carcinoma,ex_cap_promise_pole, | |
| promise.molecular_classification.mmrd,promise/2017,molecular_classification,mmrd,Mismatch repair-deficient carcinoma,ex_cap_promise_mmrd, | |
| promise.molecular_classification.p53abn,promise/2017,molecular_classification,p53abn,p53-abnormal carcinoma,ex_cap_promise_p53abn, | |
| promise.molecular_classification.nsmp,promise/2017,molecular_classification,nsmp,No specific molecular profile (NSMP),ex_cap_promise_nsmp, | |
| promise.molecular_classification.double_classifier,promise/2017,molecular_classification,double_classifier,Double classifier,ex_cap_promise_double,"Two classifiers at once is its own value, never a tie broken silently." | |
| tcga_ucec.molecular_classification.pole_ultramutated,tcga_ucec/2013,molecular_classification,pole_ultramutated,POLE-mutated (ultramutated) carcinoma,ex_cap_tcga_ultramutated, | |
| tcga_ucec.molecular_classification.msi_hypermutated,tcga_ucec/2013,molecular_classification,msi_hypermutated,Microsatellite instability high (hypermutated) carcinoma,ex_cap_tcga_msi_high, | |
| tcga_ucec.molecular_classification.copy_number_low,tcga_ucec/2013,molecular_classification,copy_number_low,Copy number low carcinoma,ex_cap_tcga_cn_low, | |
| tcga_ucec.molecular_classification.copy_number_high,tcga_ucec/2013,molecular_classification,copy_number_high,Copy number high carcinoma,ex_cap_tcga_cn_high,Routes to p53abn as a ~95% surrogate. Open decision 3. | |
| ajcc_8.regional_lymph_node_status.pN0_i_plus,ajcc/8,regional_lymph_node_status,pN0(i+),"Isolated tumor cells, no greater than 0.2 mm",ex_cap_ajcc_pn0i_plus,Does not upstage. | |
| ajcc_8.regional_lymph_node_status.pN1mi,ajcc/8,regional_lymph_node_status,pN1mi,"Micrometastasis, greater than 0.2 mm and not greater than 2.0 mm",ex_cap_ajcc_pn1mi, | |
| ajcc_8.regional_lymph_node_status.pN1a,ajcc/8,regional_lymph_node_status,pN1a,"Macrometastasis to pelvic lymph nodes, greater than 2.0 mm",ex_cap_ajcc_pn1a, | |
| fhir_dar.data_absent_reason.not_applicable,fhir_dar/1.0.0,data_absent_reason,not-applicable,Not Applicable,ex_fhir_dar_not_applicable,"Replaces the locally invented name `not_applicable`. Decided by a gate, which is itself a reviewed value." | |
| fhir_dar.data_absent_reason.asked_unknown,fhir_dar/1.0.0,data_absent_reason,asked-unknown,Asked But Unknown,ex_fhir_dar_asked_unknown,Replaces the locally invented name `not_stated`. Not `not-asked`: the escalating search did ask. | |
| figo_endo_1988.stage.IA,figo_endo/1988,stage,IA,Stage IA (1988): tumour limited to the endometrium,ex_abu_rustum_1988_stage_i, | |
| figo_endo_1988.stage.IB,figo_endo/1988,stage,IB,Stage IB (1988): invasion of less than half the myometrium,ex_abu_rustum_1988_stage_i,Opposite extent to 2009 IB (dec_015). | |
| figo_endo_1988.stage.IC,figo_endo/1988,stage,IC,Stage IC (1988): invasion of half or more of the myometrium,ex_abu_rustum_1988_stage_i,Abolished by FIGO 2009. | |
| figo_endo_2009.stage.IA,figo_endo/2009,stage,IA,Stage IA (2009): no or less than half myometrial invasion,ex_figo2009_stage_ia,Absorbs 1988 IA and IB. | |
| figo_endo_2009.stage.IB,figo_endo/2009,stage,IB,Stage IB (2009): invasion of half or more of the myometrium,ex_figo2009_stage_ib,Opposite extent to 1988 IB (dec_015). | |
| figo_endo_2009.stage.II,figo_endo/2009,stage,II,Stage II (2009): tumour invades cervical stroma,ex_figo2009_stage_ii, | |
| figo_endo_2023.stage.IA1,figo_endo/2023,stage,IA1,Stage IA1 (2023): non-aggressive limited to a polyp or confined to the endometrium,ex_figo2023_stage_ia1,Separates zero invasion from shallow invasion. | |
| figo_endo_2023.stage.IA2,figo_endo/2023,stage,IA2,Stage IA2 (2023): non-aggressive with less than half invasion and no or focal LVSI,ex_figo2023_stage_ia2,Substantial LVSI removes a case to IIB. | |
| figo_endo_2023.stage.IA3,figo_endo/2023,stage,IA3,Stage IA3 (2023): low-grade endometrioid limited to uterus and ovary,ex_figo2023_stage_ia3,Needs ovarian capsule status the corpus rarely records. | |
| figo_endo_2023.stage.IB,figo_endo/2023,stage,IB,Stage IB (2023): non-aggressive with half or more invasion and no or focal LVSI,ex_figo2023_stage_ib,Substantial LVSI removes a case to IIB. | |
| figo_endo_2023.stage.IC,figo_endo/2023,stage,IC,Stage IC (2023): aggressive histotype with no myometrial invasion,ex_figo2023_stage_ic, | |
| figo_endo_2023.stage.IIA,figo_endo/2023,stage,IIA,Stage IIA (2023): non-aggressive with cervical stromal invasion,ex_figo2023_stage_iia, | |
| figo_endo_2023.stage.IIB,figo_endo/2023,stage,IIB,Stage IIB (2023): non-aggressive with substantial LVSI,ex_figo2023_stage_iib,The IB-versus-IIB constrained pair when LVSI is unquantified. | |
| figo_endo_2023.stage.IIC,figo_endo/2023,stage,IIC,Stage IIC (2023): aggressive histotype with any myometrial invasion,ex_figo2023_stage_iic, | |
| figo_endo_2023.stage.IAmPOLEmut,figo_endo/2023,stage,IAmPOLEmut,Stage IAmPOLEmut (2023): POLEmut molecular downstage over stage I/II,ex_figo2023_stage_iam_polemut,Determined_by_join via cBioPortal. | |
| figo_endo_2023.stage.IICmp53abn,figo_endo/2023,stage,IICmp53abn,Stage IICmp53abn (2023): p53abn molecular upstage over stage I/II,ex_figo2023_stage_iicm_p53abn,Determined_by_join via cBioPortal (dec_019). | |
| iccr_endo.histotype.endometrioid,iccr_endo/5,histotype,endometrioid,Endometrioid carcinoma,ex_iccr_histotype_endometrioid,WHO 2020 value list (Note 8). | |
| iccr_endo.histotype.serous,iccr_endo/5,histotype,serous,Serous carcinoma,ex_iccr_histotype_serous,WHO 2020 value list (Note 8). | |
| iccr_endo.histotype.clear_cell,iccr_endo/5,histotype,clear_cell,Clear cell carcinoma,ex_iccr_histotype_clear_cell,WHO 2020 value list (Note 8). | |
| iccr_endo.histotype.undifferentiated,iccr_endo/5,histotype,undifferentiated,"Carcinoma, undifferentiated",ex_iccr_histotype_undifferentiated,ICCR lists undifferentiated but no separate dedifferentiated option; this registry keeps them distinct. | |
| iccr_endo.histotype.mixed,iccr_endo/5,histotype,mixed,Mixed cell carcinoma,ex_iccr_histotype_mixed,WHO 2020 value list (Note 8). | |
| iccr_endo.histotype.carcinosarcoma,iccr_endo/5,histotype,carcinosarcoma,Carcinosarcoma,ex_iccr_histotype_carcinosarcoma,ICCR adds epithelial/sarcomatous percentage and homologous/heterologous sub-detail (non-core). | |
| iccr_endo.histotype.mesonephric,iccr_endo/5,histotype,mesonephric,Mesonephric carcinoma,ex_iccr_histotype_mesonephric,Named by WHO 2020/ICCR; this registry holds it only in the other_not_listed residual. | |
| iccr_endo.histotype.squamous,iccr_endo/5,histotype,squamous,Squamous cell carcinoma,ex_iccr_histotype_squamous,Named by WHO 2020/ICCR; not itemized in this registry's histotype set. | |
| iccr_endo.histotype.mucinous_gi,iccr_endo/5,histotype,mucinous_gi,"Mucinous carcinoma, gastrointestinal type",ex_iccr_histotype_mucinous_gi,Named by WHO 2020/ICCR; CAP folds mucinous into extensive mucinous differentiation. | |
| iccr_endo.histotype.mesonephric_like,iccr_endo/5,histotype,mesonephric_like,Mesonephric-like carcinoma,ex_iccr_histotype_mesonephric_like,Named by WHO 2020/ICCR; not itemized in this registry's histotype set. | |
| iccr_endo.histotype.neuroendocrine,iccr_endo/5,histotype,neuroendocrine,Neuroendocrine carcinomas,ex_iccr_histotype_neuroendocrine,Named by WHO 2020/ICCR; subtype is non-core in ICCR. | |
| iccr_endo.histologic_grade.1,iccr_endo/5,histologic_grade,1,Grade 1 (low),ex_iccr_histologic_grade_1,FIGO grade 1; ICCR groups grades 1 and 2 as low grade (Note 9). | |
| iccr_endo.histologic_grade.2,iccr_endo/5,histologic_grade,2,Grade 2 (low),ex_iccr_histologic_grade_2,FIGO grade 2; low grade in the ICCR binary grouping (Note 9). | |
| iccr_endo.histologic_grade.3,iccr_endo/5,histologic_grade,3,Grade 3 (high),ex_iccr_histologic_grade_3,FIGO grade 3; high grade in the ICCR binary grouping (Note 9). | |
| iccr_endo.histologic_grade.not_applicable,iccr_endo/5,histologic_grade,not_applicable,Not applicable (high grade by definition),ex_iccr_histologic_grade_not_applicable,Grade recorded as not applicable for non-endometrioid tumours that are high grade by definition (Note 9). | |
| iccr_endo.myometrial_invasion.none,iccr_endo/5,myometrial_invasion,none,None (not identified),ex_iccr_myometrial_invasion_bands,"Core categorical band. CAP stores the primitive depth/thickness quantity, not a category (numbers stay numbers)." | |
| iccr_endo.myometrial_invasion.lt_50,iccr_endo/5,myometrial_invasion,lt_50,<50%,ex_iccr_myometrial_invasion_bands,Core categorical band: less than half the myometrial thickness. | |
| iccr_endo.myometrial_invasion.ge_50,iccr_endo/5,myometrial_invasion,ge_50,>=50%,ex_iccr_myometrial_invasion_bands,Core categorical band: half or more of the myometrial thickness. | |
| iccr_endo.cervical_stromal_involvement.involved,iccr_endo/5,cervical_stromal_involvement,involved,Involved,ex_iccr_cervical_stromal_involvement_involved,Core (Note 14); stages non-aggressive types as FIGO 2023 IIA. CAP stores cervical invasion as depth/percent. | |
| iccr_endo.cervical_stromal_involvement.not_involved,iccr_endo/5,cervical_stromal_involvement,not_involved,Not involved,ex_iccr_cervical_stromal_involvement_not_involved,The negative response option under CERVICAL STROMA (Note 14). | |
| iccr_endo.lvsi.not_identified,iccr_endo/5,lvsi,not_identified,Not identified,ex_iccr_lvsi_not_identified,Core (Note 11); no tumour cells within vessels. | |
| iccr_endo.lvsi.focal,iccr_endo/5,lvsi,focal,Focal,ex_iccr_lvsi_focal,Present but below the substantial cut-off (fewer than three vessels). | |
| iccr_endo.lvsi.substantial,iccr_endo/5,lvsi,substantial,"Extensive/Substantial (>=3 vessels, ISGyP)",ex_iccr_lvsi_substantial,"ICCR/ISGyP cut-off is three or more involved vessels; WHO 2020, FIGO 2023 and ESGO use five or more." | |
| iccr_endo.lvsi.indeterminate,iccr_endo/5,lvsi,indeterminate,Indeterminate,ex_iccr_lvsi_indeterminate,"Genuine doubt whether LVI is present; distinct from CAP 'cannot be determined', which asserts non-assessability (dec_016)." | |
| iccr_endo.regional_lymph_node_status.itc,iccr_endo/5,regional_lymph_node_status,itc,"Isolated tumour cells, pN0(i+)",ex_iccr_regional_lymph_node_status_itc,"<=0.2 mm and <=200 cells; not metastatic, recorded pN0(i+) (Note 25)." | |
| iccr_endo.regional_lymph_node_status.micrometastasis,iccr_endo/5,regional_lymph_node_status,micrometastasis,"Micrometastasis, pN1(mi)",ex_iccr_regional_lymph_node_status_deposit_bounds,>0.2 mm and <=2 mm; metastatic (Note 25). | |
| iccr_endo.regional_lymph_node_status.macrometastasis,iccr_endo/5,regional_lymph_node_status,macrometastasis,Macrometastasis (>2 mm),ex_iccr_regional_lymph_node_status_deposit_bounds,"Group-agnostic: pelvic macro is pN1a, para-aortic macro is pN2a (Note 25)." | |
| iccr_endo.molecular_classification.polemut,iccr_endo/5,molecular_classification,polemut,POLEmut (POLE-ultramutated),ex_iccr_molecular_classification_polemut,"TCGA-based classification, non-core (Note 26)." | |
| iccr_endo.molecular_classification.mmrd,iccr_endo/5,molecular_classification,mmrd,MMRd (hypermutated),ex_iccr_molecular_classification_mmrd,"TCGA-based classification, non-core (Note 26)." | |
| iccr_endo.molecular_classification.p53abn,iccr_endo/5,molecular_classification,p53abn,p53abn (copy-number high),ex_iccr_molecular_classification_p53abn,Abnormal p53 IHC is the ~95% surrogate for the TCGA copy-number-high group (Note 26). | |
| iccr_endo.molecular_classification.nsmp,iccr_endo/5,molecular_classification,nsmp,NSMP (no specific molecular profile),ex_iccr_molecular_classification_nsmp,Corresponds to the TCGA copy-number-low group (Note 26). | |
| iccr_endo.stage.IA1,iccr_endo/5,stage,IA1,Stage IA1 (FIGO 2023),ex_iccr_stage_IA1,ICCR incorporates the FIGO 2023 staging system (Note 28). | |
| iccr_endo.stage.IA2,iccr_endo/5,stage,IA2,Stage IA2 (FIGO 2023),ex_iccr_stage_IA2,ICCR incorporates FIGO 2023 (Note 28). | |
| iccr_endo.stage.IA3,iccr_endo/5,stage,IA3,Stage IA3 (FIGO 2023),ex_iccr_stage_IA3,ICCR incorporates FIGO 2023 (Note 28). | |
| iccr_endo.stage.IB,iccr_endo/5,stage,IB,Stage IB (FIGO 2023),ex_iccr_stage_IB,ICCR incorporates FIGO 2023 (Note 28). | |
| iccr_endo.stage.IC,iccr_endo/5,stage,IC,Stage IC (FIGO 2023),ex_iccr_stage_IC,ICCR incorporates FIGO 2023 (Note 28). | |
| iccr_endo.stage.IIA,iccr_endo/5,stage,IIA,Stage IIA (FIGO 2023),ex_iccr_stage_IIA,ICCR incorporates FIGO 2023 (Note 28). | |
| iccr_endo.stage.IIB,iccr_endo/5,stage,IIB,Stage IIB (FIGO 2023),ex_iccr_stage_IIB,ICCR incorporates FIGO 2023 (Note 28). | |
| iccr_endo.stage.IIC,iccr_endo/5,stage,IIC,Stage IIC (FIGO 2023),ex_iccr_stage_IIC,ICCR incorporates FIGO 2023 (Note 28). | |